randomized controlled trials

You have accessRestricted Access
Authors’ Reply
Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, Yoshikatsu Majikawa and Michael Reusch

JASN September 2020, ASN.2020071096; DOI: https://doi.org/10.1681/ASN.2020071096

Add to Selected Citations
You have accessRestricted Access
Pilot Trials in Nephrology: Establishing a BASE for Large-Scale Randomized Trials
Brendon L. Neuen and Vlado Perkovic

JASN January 2020, 31 (1) 4-6; DOI: https://doi.org/10.1681/ASN.2019111196

Add to Selected Citations
You have accessRestricted Access
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
Lesley A. Inker, Hiddo J. L. Heerspink, Hocine Tighiouart, Andrew S. Levey, Josef Coresh, Ron T. Gansevoort, Andrew L. Simon, Jian Ying, Gerald J. Beck, Christoph Wanner, Jürgen Floege, Philip Kam-Tao Li, Vlado Perkovic, Edward F. Vonesh and Tom Greene

JASN September 2019, 30 (9) 1735-1745; DOI: https://doi.org/10.1681/ASN.2019010007

Add to Selected Citations
You have accessRestricted Access
The Case for Selective Withdrawal of Antidepressants in Patients with Advanced Kidney Disease
Joseph Chilcot and Ken Farrington

JASN July 2019, 30 (7) 1339-1340; DOI: https://doi.org/10.1681/ASN.2019030308

Add to Selected Citations
You have accessRestricted Access
Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers
Wing-Chi G. Yeung, Nigel D. Toussaint and Sunil V. Badve

JASN June 2019, 30 (6) 909-910; DOI: https://doi.org/10.1681/ASN.2019040333

Add to Selected Citations
Open Access
Persistent Underrepresentation of Kidney Disease in Randomized, Controlled Trials of Cardiovascular Disease in the Contemporary Era
Rohit Maini, David B. Wong, Daniel Addison, Elizabeth Chiang, Steven D. Weisbord and Hani Jneid

JASN December 2018, 29 (12) 2782-2786; DOI: https://doi.org/10.1681/ASN.2018070674

Add to Selected Citations
Open Access
Translational Methods in Nephrology: Individual Treatment Effect Modeling
F. Perry Wilson and Chirag R. Parikh

JASN November 2018, 29 (11) 2615-2618; DOI: https://doi.org/10.1681/ASN.2018060629

Add to Selected Citations
You have accessRestricted Access
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
Christoph Wanner, Hiddo J.L. Heerspink, Bernard Zinman, Silvio E. Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Stefan Hantel, Hans-Juergen Woerle, Uli C. Broedl, Maximilian von Eynatten, Per-Henrik Groop and on behalf of the EMPA-REG OUTCOME Investigators

JASN November 2018, 29 (11) 2755-2769; DOI: https://doi.org/10.1681/ASN.2018010103

Add to Selected Citations
You have accessRestricted Access
Transformation in Immunosuppression: Are We Ready for it?
Amtul Aala and Daniel C. Brennan

JASN July 2018, 29 (7) 1791-1792; DOI: https://doi.org/10.1681/ASN.2018050491

Add to Selected Citations
You have accessRestricted Access
Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy
Barbara Seitz-Polski, Hanna Debiec, Alexandra Rousseau, Karine Dahan, Christelle Zaghrini, Christine Payré, Vincent L.M. Esnault, Gérard Lambeau and Pierre Ronco

JASN February 2018, 29 (2) 401-408; DOI: https://doi.org/10.1681/ASN.2017070734

Add to Selected Citations

Main menu

User menu

Search

randomized controlled trials

Pages

About

Author Information

More Information